Company* (Country; Symbol) |
Company |
Type/Product Area |
Terms/Details (Date) |
|
| |||
Neurobiological Technologies Inc. (NTII) |
Celtic Pharma Holdings LP (Bermuda) |
Celtic, an equity firm, got rights to Xercept, a product in Phase III trials for swelling associated with brain tumors |
NTI gets $33 million in up-front payments and up to $15M more if regulatory objectives are reached; it would have a profit-sharing arrangement in the U.S. and get royalties on sales outside the U.S. (9/20) |
| |||
NewGen Technologies Inc. (OTC BB: NWGN) |
Advanced Biotechnology Inc. |
They formed a joint venture to build and operate biodiesel plants in the Southeast |
The venture between NewGen subsidiary ReFuel America Inc., and ABI will be named Advanced Biotechnologies LLC; terms were not disclosed (9/14) |
| |||
|
Novavax Inc. (NVAX) |
Pharmelle LLC |
Novavax sold the non-core products AVC Cream, NovaNatal and NovaStart to Pharmelle |
Novavax got $2.5M and would get royalty payments if product sales exceed certain levels (9/23) |
|
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
OTC BB = Over-the-Counter Bulletin Board. | |||
To read more on related topics, click on one of the words below.